» LEARN ABOUT COVID-19 VARIANTS, VACCINES, TESTING, & VISITOR REQUIREMENTS

MyHealth

Manage your account, request prescriptions, set up appointments & more.

LOG IN
Don't have an account
Contact Us
    • see more mega-menu-label
    • see more mega-menu-label
    • see more mega-menu-label
    • see more mega-menu-label
    • see more mega-menu-label
    • see more mega-menu-label
    • see more mega-menu-label

COG-AAML1031

Trial

Clinical Trial Title

Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia

Trial Status

Open to Enrollment

Start Date

January 3, 2012

Trial Type

Pediatric Cancer (Oncology)

Specific Condition

Acute Myeloid Leukemia (AML)

Description

This randomized phase III trial studies how well bortezomib and sorafenib tosylate work in treating patients with newly diagnosed acute myeloid leukemia. Bortezomib and sorafenib tosylate may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving bortezomib and sorafenib tosylate together with combination chemotherapy may be an effective treatment for acute myeloid leukemia.

Eligibility Criteria

Age: <30 years of age at the time of study enrollment

Newly diagnosed with de novo Acute Myelogenous Leukemia (AML)

Patients with previously untreated primary AML who meet the customary criteria for AML with >20% bone marrow blasts

Patients with biopsy proven isolated myeloid sarcoma (myeloblastoma; chloroma, including leukemia cutis) are eligible

Prior therapy with hydroxyurea, all-trans retinoic acid (ATRA), corticosteroids (any route), and IT cytarabine given at diagnosis is allowed

Hydroxyurea and ATRA must be discontinued prior to initiation of protocol therapy

Patients who have previously received any other chemotherapy, radiation therapy, or any other anti-leukemic therapy are not eligible for this study

Notes

https://clinicaltrials.gov/ct2/show/NCT01371981

Study status is:
Active, not recruiting: The study is ongoing, and participants are receiving an intervention or being examined, but potential participants are not currently being recruited or enrolled.

Principal Investigator Name

Janice Olson, MD

Contact Name

Children's Cancer and Blood Disorders Program

Phone

(503) 276-9300

Last Updated: Wednesday, January 27, 2021 11:41:08 AM